Quantcast

Latest Vanda Pharmaceuticals Inc. Stories

2011-08-04 06:00:00

ROCKVILLE, Md., Aug. 4, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the second quarter and six months ended June 30, 2011. "We are pleased with our progress towards our vision of building a CNS specialty pharmaceutical company. Fanapt® scripts in the U.S....

2011-08-01 06:00:00

ROCKVILLE, Md., August 1, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced its exclusive license agreement with Argentina-based Biotoscana Farma S.A., a wholly owned affiliate of Biotoscana International, based in Bogota, Colombia, for the commercialization of Fanapt (TM) in Argentina. "We are very excited to achieve this...

2011-07-26 06:00:00

ROCKVILLE, Md., July 26, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) announced today that the European Medicines Agency (EMA) accepted for evaluation Vanda's Marketing Authorization Application (MAA) for oral iloperidone tablets. Iloperidone is an atypical antipsychotic for the treatment of schizophrenia in adults. "The submission in the European Union is an important milestone towards advancing the iloperidone franchise," said Mihael H. Polymeropoulos, M.D., Vanda's...

2011-07-20 14:00:00

ROCKVILLE, Md., July 20, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced it will release results for the second quarter of 2011, on Thursday, August 4, 2011, before the market opens. A full text copy of the release will be disseminated at that time. Mihael H. Polymeropoulos, M.D., President and Chief Executive Officer, will...

2011-07-11 06:00:00

ROCKVILLE, Md., July 11, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced its exclusive license agreement with Probiomed S.A. de C.V., a wholly owned pharmaceutical operating unit of Proquifin S.A. de C.V., for the commercialization of Fanapt(TM) in Mexico. "We are very excited to achieve this step on the path towards making...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related